XML 55 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity (Tables)
 12 Months Ended
Jun. 30, 2023
Stockholders' Equity Note [Abstract]  
Schedule of Activity of Restricted Stock Units
The following table summarizes the activity of RSUs, including PRSUs, during year ended June 30, 2023 (in thousands, except years and per share amounts):
Restricted
Stock
Units		Weighted
Average
Grant-Date
Fair Value		Weighted
Average
Remaining
Contractual
Term in Years
Outstanding at beginning of period681 $203.46 1.6
Granted434 224.02 
Vested*(416)160.50 
Performance factor adjustment115 — 
Forfeited (52)216.75 
Outstanding at end of period762 $227.82 1.7
*Includes 139 thousand shares netted for tax.
Schedule of Option Activity
The following table summarizes option activity during the year ended June 30, 2023 (in thousands, except years and per share amounts):
OptionsWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Term in Years
Outstanding at beginning of period938 $112.91 3.2
Granted100 223.94 
Exercised(157)62.07 
Forfeited— — 
Outstanding at end of period881 $134.52 3.0
Options exercisable at end of period734 $115.37 2.4
Options vested and expected to vest at end of period873 $133.56 3.0
Schedule of Assumptions for Fair Value of Stock Option Plans and Purchase Rights Granted
We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions for the years ended June 30, 2023, 2022 and 2021:
202320222021
Stock options:
Weighted average grant date fair value$74.95$72.16$53.67
Weighted average risk-free interest rate3.85%1.29%0.37%
Expected life in years4.94.94.9
Dividend yield0.78%0.66%0.75%
Expected volatility34%32%31%
ESPP purchase rights:
Weighted average grant date fair value$52.38$50.46$48.18
Weighted average risk-free interest rate3.6%0.3%0.1%
Expected life in years6 months6 months6 months
Dividend yield
0.75% - 0.84%
0.63% - 0.98%
0.79% - 0.98%
Expected volatility
27% - 34%
20% - 34%
30% - 60%
Schedule of Total Stock-Based Compensation Costs Incurred and Associated Tax Benefit Recognized
The following table summarizes the total stock-based compensation costs incurred and the associated tax benefit recognized during the years ended June 30, 2023, 2022 and 2021 (in thousands):
202320222021
Cost of sales $6,465 $5,218 $4,153 
Selling, general and administrative expenses53,049 50,791 51,727 
Research and development expenses11,628 9,248 8,047 
Stock-based compensation costs71,142 65,257 63,927 
Tax benefit(24,860)(29,262)(23,346)
Stock-based compensation costs, net of tax benefit$46,282 $35,995 $40,581